ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.122,25
0,95%
S&P 500
5.064,20
0,91%
US Dollar vs BRL
5,1111
-0,01%
Bitcoin
59.396,58
0,47%
Brent Oil
83,635
0,01%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Novartis AG (NVS)

  7. Novartis AG (NVS) Notícias

NVS

Novartis (NVS)

Novartis AG
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:NVS
DataHoraFonteTítuloCódigoCompanhia
23/04/202408:25IH Market NewsApple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More NewsNYSE:NVSNovartis AG
15/04/202415:00PR Newswire (US)New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)NYSE:NVSNovartis AG
11/04/202408:00GlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNYSE:NVSNovartis AG
10/04/202408:13IH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:NVSNovartis AG
06/04/202417:16PR Newswire (US)New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world settingNYSE:NVSNovartis AG
15/02/202418:15Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNYSE:NVSNovartis AG
06/02/202418:52Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNYSE:NVSNovartis AG
06/02/202408:14IH Market NewsBoeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and MoreNYSE:NVSNovartis AG
02/02/202416:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:NVSNovartis AG
31/01/202409:44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:NVSNovartis AG
31/01/202409:42Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NYSE:NVSNovartis AG
31/01/202409:38Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NYSE:NVSNovartis AG
31/01/202408:28IH Market NewsWalmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and MoreNYSE:NVSNovartis AG
22/01/202403:59Dow Jones NewsSandoz to Acquire Cimerli Business from Coherus for $170 MillionNYSE:NVSNovartis AG
12/01/202408:10IH Market NewsWall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and MoreNYSE:NVSNovartis AG
11/01/202415:02Dow Jones NewsCytokinetics Shares Slide as Novartis Reportedly Shies Away From DealNYSE:NVSNovartis AG
08/01/202415:43Dow Jones NewsCytokinetics Shares Jump 16% After WSJ Report of Novartis DealNYSE:NVSNovartis AG
08/01/202412:41Dow Jones NewsNovartis on Track for Record High Close -- Data TalkNYSE:NVSNovartis AG
08/01/202404:01Dow Jones NewsNovartis's Scemblix Drug Meets Main Goals in Late-Stage Leukemia TrialNYSE:NVSNovartis AG
05/01/202412:15Dow Jones NewsNovartis to Make Pluvicto Radioligand Therapy at Indianapolis PlantNYSE:NVSNovartis AG
02/01/202409:46Dow Jones NewsVoyager Therapeutics Shares Leap Premarket on Novartis CollaborationNYSE:NVSNovartis AG
11/12/202304:02Dow Jones NewsNovartis Drug Meets Primary Goal in Late-Stage Study for Kidney DiseaseNYSE:NVSNovartis AG
10/12/202321:39PR Newswire (US)Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)NYSE:NVSNovartis AG
06/12/202307:14Dow Jones NewsMerck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage TrialsNYSE:NVSNovartis AG
06/12/202302:18PR Newswire (US)Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHNYSE:NVSNovartis AG
05/12/202308:25IH Market NewsMoody’s Reassesses China, GitLab Exceeds Estimates, Twilio Plans Major Layoffs, and MoreNYSE:NVSNovartis AG
29/11/202308:18IH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNYSE:NVSNovartis AG
28/11/202317:08Dow Jones NewsFDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood CellsNYSE:NVSNovartis AG
28/11/202304:12Dow Jones NewsNovartis Raises Mid-Term Sales Growth TargetsNYSE:NVSNovartis AG
13/11/202311:16Dow Jones NewsLegend Biotech Subsidiary in License Agreement With NovartisNYSE:NVSNovartis AG
 Apresentando as notícias mais relevantes sobre:NYSE:NVS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BBDC4
BRADESCO PN
BOV
PRIO3
PETRORIO ON
BOV
GOLL4
GOL PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
BEES3
BANESTES ON
BOV
COGN3
COGNA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados